



General Assembly

Substitute Bill No. 241

February Session, 2024



**AN ACT CONCERNING THE OFFICE OF HEALTH STRATEGY'S
RECOMMENDATIONS REGARDING 340B PROGRAM
TRANSPARENCY.**

Be it enacted by the Senate and House of Representatives in General Assembly convened:

1 Section 1. (NEW) (*Effective October 1, 2024*) (a) As used in this section,
2 (1) "federal 340B Drug Pricing Program" or "program" means the plan
3 described in Section 340B of the Public Health Service Act, 42 USC 256b,
4 as amended from time to time, and (2) "340B covered entity" means an
5 entity authorized to participate in the federal 340B Drug Pricing
6 Program under 42 USC 256b(a)(4), as amended from time to time.

7 (b) Not later than April 1, 2025, and annually thereafter, each 340B
8 covered entity shall report to the Health Systems Planning Unit of the
9 Office of Health Strategy, in a form and manner prescribed by the
10 executive director of the Office of Health Strategy, information
11 regarding such entity's participation in the federal 340B Drug Pricing
12 Program. Such report shall include (1) the aggregated acquisition cost
13 for prescription drugs obtained under the program, (2) the aggregated
14 payment amount received for prescription drugs obtained for and
15 dispensed to patients under the program, (3) the aggregated payments
16 made to pharmacies under contract to dispense prescription drugs
17 obtained under the program, (4) the number of claims for prescription
18 drugs described in subdivision (2) of this subsection, (5) if the 340B

19 covered entity is a hospital licensed pursuant to chapter 368v of the
20 general statutes, the national drug code number for the fifty most
21 frequently dispensed prescription drugs by the hospital under the
22 program, and (6) a description of programs and services offered by the
23 340B covered entity, including, but not limited to, programs and
24 services that support community access to care, that are funded in whole
25 or in part by savings gained through participation in the program and
26 that the 340B covered entity could not continue offering without such
27 savings. The information required to be reported pursuant to this
28 subsection shall (A) be disaggregated by payer mix, including, but not
29 limited to, Medicare, Medicaid and private insurance, as prescribed by
30 the executive director, and (B) include prescription drugs dispensed by
31 outpatient facilities that are child sites listed as reimbursable facilities
32 on a hospital's Medicare cost report.

33 (c) The executive director of the Office of Health Strategy shall post a
34 summary of the aggregate information received by the unit pursuant to
35 the provisions of this section on the Office of Health Strategy's Internet
36 web site.

This act shall take effect as follows and shall amend the following sections:		
Section 1	<i>October 1, 2024</i>	New section

PH *Joint Favorable Subst.*